OptimizeRx Corporation
OPRX
$6.51
$0.081.29%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.24% | 22.33% | 55.19% | 11.37% | 13.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.24% | 22.33% | 55.19% | 11.37% | 13.91% |
| Cost of Revenue | -20.93% | 8.76% | 48.56% | 14.67% | -2.23% |
| Gross Profit | 9.43% | 30.26% | 59.22% | 9.34% | 23.44% |
| SG&A Expenses | -17.40% | 7.16% | -0.06% | -11.15% | 16.91% |
| Depreciation & Amortization | -1.46% | -1.37% | 0.09% | 2.53% | 8.64% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.06% | 7.30% | 15.27% | -2.74% | 8.87% |
| Operating Income | 130.51% | 291.05% | 185.06% | 57.96% | 72.46% |
| Income Before Tax | 238.36% | 110.55% | 133.61% | 49.90% | 118.81% |
| Income Tax Expenses | 7.22% | 133.05% | 116.64% | -415.41% | 130.09% |
| Earnings from Continuing Operations | 6,535.90% | 108.54% | 138.22% | 68.13% | 98.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6,535.90% | 108.54% | 138.22% | 68.13% | 98.12% |
| EBIT | 130.51% | 291.05% | 185.06% | 57.96% | 72.46% |
| EBITDA | 94.11% | 2,365.91% | 247.08% | 71.28% | 55.51% |
| EPS Basic | 6,504.76% | 108.42% | 137.72% | 68.63% | 98.20% |
| Normalized Basic EPS | 215.50% | 142.22% | 133.14% | 50.73% | 67.74% |
| EPS Diluted | 6,169.05% | 108.00% | 136.36% | 68.42% | 98.26% |
| Normalized Diluted EPS | 203.85% | 140.31% | 132.28% | 50.73% | 67.74% |
| Average Basic Shares Outstanding | 1.32% | 1.38% | 1.39% | 1.65% | 3.61% |
| Average Diluted Shares Outstanding | 5.23% | 6.20% | 4.15% | 1.65% | 3.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |